The Imugene Limited (ASX: IMU) share price is through the roof today, breaking record highs.
At the time of writing, shares in the medical research and development company are up 11.5%, trading at a record high of 14.5 cents each. By comparison, the S&P/ASX All Ordinaries Index (ASX: XAO) is 0.58% higher.
Today’s positive price movement comes as the company made a major announcement on its latest medical treatment.
Let’s delve deeper and see how it’s affecting the Imugene share price.
What’s pushing the Imugene share price higher?
In today’s ASX statement, Imugene advised that Phase I trials of its lung cancer vaccine, PD1-Vaxx, would “proceed to the third and final highest dose cohort”.
The company said an independent expert committee found the vaccine safe for humans at the mid-level dosage of 50 micrograms. The trial will now proceed to the full dosage of 100 micrograms.
According to the company, the results showed that one patient’s tumour almost completely disappeared after 6 weeks, while three others stabilised. One patient’s disease, however, did further progress. After 85 days, the status of two patients was unchanged.
Imugene says these early results are promising signs of the vaccine’s efficacy. The company also advised that the Mayo Clinic in Phoenix, Arizona, had received approval to join the Phase 1 clinical trial of PD1-Vaxx in the United States.
Stakeholder commentary
Principal investigator, Professor Gary Richards of Cabrini Hospital, Melbourne, said
I am excited to hear the Cohort Review Committee recommended opening the third and final dose cohort based on the outstanding safety and tolerability of PD1-Vaxx reviewed to date.
Imugene managing director and CEO Leslie Chong added:
Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development. I am encouraged that we are seeing positive signals at such an early stage of our PD1-Vaxx Phase I trial.
Imugene share price snapshot
Over the last 12 months, the Imugene share price increased by 625% and is now at an all-time high. In fact, in the past 6 months, the company’s share price value has increased by 141%.
At its current share price, Imugene has a market capitalisation of $676.8 million.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
More reading
- ASX 200 up 0.25%: EML surges on acquisition news, Westpac’s APRA update
- Amazon just passed a major milestone in the digital advertising market
- The Fiji Kava (ASX:FIJ) share price rocketed 26% this morning. Here’s why
- Why EML, NextDC, Qantas, & Recce shares are racing higher
- Why the MGC Pharma (ASX:MXC) share price is zooming 13% higher today
Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Why the Imugene (ASX:IMU) share price just hit an all-time high appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/3utiZFL
Leave a Reply